Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

Introduction<p>Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the increasing use of Janus kinase (JAK) inhibitors in immune-related conditions, their potential role in AA treatment is gaining attention. Deuruxolitinib has emerged as a potential treatmen...

Mô tả đầy đủ

Đã lưu trong:
Chi tiết về thư mục
Tác giả chính: Mulham Kalantan (20970761) (author)
Tác giả khác: Bader Bashrahil (14429241) (author), Abdulaziz Aljuaid (22385410) (author), Hassan Bogari (20970767) (author), Sahal Samarkandy (5164802) (author), Abdulhadi Jfri (9447565) (author)
Được phát hành: 2025
Những chủ đề:
Foetal Development and Medicine
alopecia
alopecia aerata (AA)
biologic
deuruxolitinib
CTP-543
JAK inhibitor
Các nhãn: Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự